Francesco Galimi compensation by year
Adicet Bio Summary Compensation Table · all 4 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Salary | $105,000 | $389,212 | $412,800 | $443,404 |
| Bonus | $162,500 | $162,500 | $0 | $0 |
| Stock awards | — | $0 | $650,400 | $0 |
| Option awards | $347,480 | $821,610 | $1,039,071 | $1,308,662 |
| Non-equity incentive | $29,400 | $115,790 | $198,240 | $195,360 |
| Pension and deferred compensation | — | $0 | $0 | $0 |
| All other | $15,370 | $38,677 | $40,349 | $41,601 |
| Total | $659,750 | $1,527,789 | $2,340,860 | $1,989,027 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adicet Bio, Inc. DEF 14A filed April 18, 2023, accession 0000950170-23-013294, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Adicet Bio, Inc. filed document, accession 0000950170-23-013294. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 16,000 | $118,080 | — |
| Option | 33,806 | — | $16.11 |
| Option | 15,384 | — | $16.82 |
| Option | 96,355 | — | $15.52 |
| Option | 24,080 | — | $5.97 |
| Option | 41,667 | — | $13.27 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Adicet Bio, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
17 Form 4 lines since the FY2022 proxy (filed April 18, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-06-05 | Grant or award derivative | — | 375,077 | $0.00 | 375,077 |
| 2024-01-24 | Grant or award | — | 26,300 | $0.00 | 101,801 |
| 2024-01-24 | Tax withholding | — | 4,957 | $2.40 | 75,501 |
| 2024-01-24 | Grant or award derivative | — | 288,134 | $0.00 | 288,134 |
| 2023-10-02 | Tax withholding | — | 8,093 | $1.37 | 80,458 |
| 2023-08-14 | Disposition to the issuer derivative | — | 77,269 | $0.00 | 0 |
| 2023-08-14 | Disposition to the issuer derivative | — | 73,964 | $0.00 | 0 |
| 2023-08-14 | Disposition to the issuer derivative | — | 113,652 | $0.00 | 0 |
The 8 most recent of 17 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Adicet Bio’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $3,988,018 |
| Blake Aftab | Chief Scientific Officer | $2,479,544 |
| Francesco Galimi · this page | Chief Medical Officer | $1,989,027 |
The full Adicet Bio compensation record
free company briefThis page is one person within Adicet Bio's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adicet Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.